A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Public ClinicalTrials.gov record NCT07293351. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC)
Study identification
- NCT ID
- NCT07293351
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 234 participants
Conditions and interventions
Conditions
Interventions
- Cabozantinib Drug
- Ipilimumab Drug
- Nivolumab Drug
- Pumitamig Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 2026
- Primary completion
- Nov 27, 2029
- Completion
- Nov 25, 2031
- Last update posted
- May 4, 2026
2026 – 2031
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0117 | New Haven | Connecticut | 06510 | Not yet recruiting |
| Sibley Memorial Hospital | Washington D.C. | District of Columbia | 20016 | Recruiting |
| Local Institution - 0126 | Orlando | Florida | 32803 | Not yet recruiting |
| Local Institution - 0124 | Iowa City | Iowa | 52242 | Not yet recruiting |
| Johns Hopkins Hospital | Baltimore | Maryland | 21287 | Recruiting |
| Washington University School of Medicine | St Louis | Missouri | 63110 | Recruiting |
| Local Institution - 0096 | Hauppauge | New York | 11788 | Not yet recruiting |
| Local Institution - 0135 | Cincinnati | Ohio | 45219 | Not yet recruiting |
| Local Institution - 0127 | Cleveland | Ohio | 44195 | Not yet recruiting |
| MUSC Hollings Cancer Center | Charleston | South Carolina | 29425 | Recruiting |
| Carolina Urologic Research Center, LLC | Myrtle Beach | South Carolina | 29572 | Recruiting |
| Local Institution - 0158 | Salt Lake City | Utah | 84112 | Withdrawn |
| Local Institution - 0095 | Seattle | Washington | 98109-1023 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 59 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07293351, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07293351 live on ClinicalTrials.gov.